drugset / Trial / NCT00418093
Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma
Phase 2
Terminated
19 enrolled
Dana-Farber Cancer Institute
Brigham and Women's Hospital · collabEli Lilly and Company · collabGenentech, Inc. · collabMassachusetts General Hospital · collabSanofi-Synthelabo · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to begin to collect information and try to learn whether or not the combination of oxaliplatin, gemcitabine and bevacizumab works in treating women with recurrent mullerian carcinoma. We will also collect more information about the safety and side effects of this combination of drugs. Gemcitabine and oxaliplatin are chemotherapy drugs that kill cancer cells. Bevacizumab is a new anti-cancer drug that works to slow or stop cell growth in cancerous tumors by decreasing the blood supply to the tumors.
Timeline
- Start
- 2006-09
- Primary completion
- 2011-01
- Completion
- 2011-10
Outcome
Outcome not reported
Stopped: “THe study was terminated early due to a lack of accural”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | Oxaliplatin | Small molecule | — | Intravenous |